9 Best Healthcare Stocks with the Highest Upside

8. CG Oncology, Inc. (NASDAQ:CGON)

Analyst Upside: 59.12%

Number of Hedge Fund Holders: 32

On October 7, CG Oncology, Inc. (NASDAQ:CGON) was initiated with a Buy rating by Guggenheim analyst Brad Canino, who assigned the stock a $90 price target.

The firm told investors in a research note that it sees the company “rising to the top of quality oncology ideas.” It added that the non-muscle invasive bladder cancer market holds considerable pricing power and a number of patients, supporting the optimistic rating for CG Oncology, Inc. (NASDAQ:CGON).

Canino also cited CG Oncology, Inc.’s (NASDAQ:CGON) cretostimogene, which would enter FDA review in 2026, as a notable factor, highlighting its “best-in-class” efficacy and safety durability.

CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The company is making significant advancements across its pipeline to develop a potential backbone bladder-sparing therapy for NMIBC. With a strong tolerability profile and safety, cretostimogene has the potential to induce a durable, complete response in bladder cancer patients.